Double-blind double-dummy crossover study of the efficacy and safety of nisoldipine (BAYk5552) versus nifedipine

C. Rosendorff, C. Goodman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Nisoldipine 10 mg once a day was compared to nifedipine 20 mg twice a day in a randomised double-blind double-dummy crossover study of efficacy and safety in thirty patients with mild to moderate essential hypertension (untreated supine phase V diastolic blood pressure of 95 to 120 mmHg) treated with each drug for eight weeks. The two agents were equally effective in reducing supine blood pressure from a mean of 165.0/104.5 (± 3.5/1.8 mmHg) to 157.5/89.6 (± 3.5/2.3) mmHg for nisoldipine and 155.3/88.2 (± 3.6/2.2) mmHg for nifedipine. Standing blood pressures were reduced from 159.6/103.6 (± 3.7/2.1) mmHg to 152.0/87.5 (± 5.6/3.1) mmHg for nisoldipine and 145.7/88.8 (± 4.2/2.4) mmHg for nifedipine. Heart rates increased significantly on nisoldipine but not on nifedipine. The side effect profile was similar, except that ankle edema was significantly more common with nifedipine. Nisoldipine is a new dihydropyridine calcium channel blocking drug that is potent, effective and relatively safe in once-daily monotherapy for mild to moderate essential hypertension.

Original languageEnglish
Pages (from-to)912-920
Number of pages9
JournalCurrent Therapeutic Research - Clinical and Experimental
Issue number5
StatePublished - 1985
Externally publishedYes


Dive into the research topics of 'Double-blind double-dummy crossover study of the efficacy and safety of nisoldipine (BAYk5552) versus nifedipine'. Together they form a unique fingerprint.

Cite this